Abstract | OBJECTIVE: METHODS: RESULTS:
After treatment, the ICP and ICP/MAP values of the GSTT were significantly higher than those of the T2DMED group (P<0.05). Unlike the T2DMED group, the GSTT group showed significantly increased NO levels (P<0.05) and decreased ROS levels (P<0.05). There was no significant difference between the GSTT group and the sildenafil group in increasing cGMP levels (P>0.05), and the mixed group had higher levels than these two groups (P<0.05). Immunohistochemistry and Western blotting showed that the expression of eNOS in the GSTT was significantly higher than that in the T2DMED groups (P<0.05). Masson staining showed that the smooth muscle/ collagen ratio of the GSTT group was significantly higher than that of the T2DMED groups (P<0.05), the expression of TIMP-1 was lower than that of T2DMED group (P<0.05). TUNEL assay showed that the apoptotic index and cleaved caspase 3 and cleaved caspase 9 expression level of GSTT group were lower than that of the T2DMED group (P<0.05). CONCLUSION: GSTT can protect T2DMED rats' erectile function by improving penile endothelial function and inhibiting cavernosum fibrosis, inhibiting apoptosis, and is synergistic with sildenafil.
|
Authors | Hui Zhang, Wen-Ting Tong, Chang-Rong Zhang, Jun-Long Li, Hao Meng, Hai-Gan Yang, Min Chen |
Journal | Diabetes, metabolic syndrome and obesity : targets and therapy
(Diabetes Metab Syndr Obes)
Vol. 12
Pg. 1705-1716
( 2019)
ISSN: 1178-7007 [Print] New Zealand |
PMID | 31564938
(Publication Type: Journal Article)
|
Copyright | © 2019 Zhang et al. |